pills web small

This page includes clinical studies seeking participants and treatment news from IFFGD Industry Council supporters Ironwood Pharmaceuticals, and Shire. No endorsement is intended or implied.

Clinical Studies Seeking Participants

A clinical study or trial is a research study to answer specific questions about new therapies or new ways of using known treatments. Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about a study, you or your doctor may contact the study research staff.

Study of Teduglutide for Treatment of Pediatric Short Bowel Syndrome (SBS)

May 31, 2016 – Participants sought for a short bowel syndrome (SBS) research study for children up to 17 years of age on parenteral nutrition. The aim of the study is to increase absorption of nutrients which may result in decreased parenteral support. Learn more

Study of Oral Budesonide for Treatment of Eosinophilic Esophagitis (EoE)

May 10, 2016 – Participants sought for a study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved. Learn more

Long-Term Study of SBS

March 3, 2014 – Participants of any age are being sought for a long-term research study of patients with short bowel syndrome (SBS). Learn more

Treatment News

Developments in drug treatments for functional GI and motility disorders.

Linaclotide (Linzess)

March 21, 2017 – Linaclotide (Linzess) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults is now available in Japan. Learn more

Linaclotide (Linzess/Constella)

January 29, 2016 – Pediatric participants sought for two studies of linaclotide for treatment in children of irritable bowel syndrome with constipation, or IBS-C (ages 7–17) and for functional constipation (ages 6–17). Learn more


December 16, 2015 – The new FDA approved drug, eluxadoline (Viberzi), is available for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in men and women. Learn more


January 5, 2015 – The Japanese Ministry of Health, Labor, and Welfare (MHLW) granted teduglutide (Gattex® in the US; Revestive® in the EU) orphan drug status for the treatment of adult patients with short bowel syndrome (SBS). Learn more


June 30, 2014 – The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gattex® (teduglutide [rDNA origin]) for injection, to include long-term data from adult patients with Short Bowel Syndrome (SBS). Learn more

Linaclotide (Linzess/Constella)

June 13, 2013 – Linaclotide is now available in Europe (branded as Costella in the EU) to treat irritable bowel syndrome with constipation (IBS-C)Learn more

What are Phases?

Treatment trials or studies are in four phases:

Phase 1 tests a new drug or treatment in a small group to evaluate its safety, determine a safe dosage range, and identify side effects;

Phase 2 expands the study to a larger group of people to see if it is effective and to further evaluate its safety;

Phase 3 expands the study to an even larger group of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely; and

Phase 4 takes place after the drug or treatment has been licensed and marketed to further evaluate it in the general population.

Medical and Treatment News
Industry Treatment News
Eosinophilic Esophagitis Study
Linaclotide (Linzess)
Medical News
Medical News - Archive (2006-2013)
Special Events & Meetings
Press Releases
2018-0801 IFFGD Raises Awareness for Gastroparesis Awareness Month to “Make Patient Voices Heard”
2018-0529 IFFGD Presents 2018 Research Recognition Awards at DDW
2018-0402 Social Taboos, Lack of Awareness May Prevent Diagnosis & Treatment of IBS
2018-0212 IFFGD Raises Awareness for Rare Disease Day 2018
2017-1114 Holiday Heartburn or Something More?
2017-0802 Research Survey Reveals Unmet Needs of People with Gastroparesis
2017-0403 IFFGD Encourages People to See Their Doctor for Symptoms of IBS
2016-1115 GERD is More Than Simple Heartburn
2016-0801 Learn the Facts About Gastroparesis
2016-0405 Think You Have IBS? Find Out For Sure Before Starting a Treatment
2015-1123 Is it More than Simple Heartburn? Ask Your Doctor.
2015-7-30 Gastroparesis is a Hidden Medical Condition for Many
2015-0330 Online Survey Looks to Help Improve Outcomes for those with IBS
2014-1119 Persistent Heartburn May Be a Sign of GERD
2014-0826 Lack of Awareness of Gastroparesis May Impact Medical Care
2014-0326 IFFGD Marks IBS Awareness Month with Launch of Mobile App
2014-0225 IFFGD Research Grants to Study Gastroparesis
2013-1106 15 Tips for GERD Awareness Week
2013-0626 New DHA.org
2013-0412 IFFGD Presents 2013 Research Awards
2013-0401 Turning Attention to Returning Vets
2012-1109 Banish Frequent Heartburn by Burning More Calories
2012-0321 April is IBS Awareness Month: A Serious Issue for Veterans
2011-1130 Is Your Child's Reflux/Spitting Up A Point of Concern?
2011-0329 IBS Signs You Should Not Ignore
2010-1118 GERD Difference
2010-1001 Heartburn or GERD?
2010-0517 US House Resolution for IBS
2009-1109 GERD at Night
2009-0417 IFFGD Research Award Recipients
2008-0331 Dealing with Digestive Disorders
2007-1118 When Is Simple Heartburn Not So Simple?
2007-0718 Proposed FDA Funding Applauded
2007-0401 IBS Myths
2006-1116 GERD & Holidays
2006-0418 Natl Commission
2006-0321 Women's Health
2006-0202 IBS or Something Else
2005-1125 GERD Costs
2005-0412 IBS Awareness
2004-1125 Heartburn & Heartache
2004-0929 Norton Honored
2004-0525 IBS Travel Tips
2003-1117 GERD Treatment
2011-0412 IFFGD Research Award Winners
2004-0408 IBS Medical Care
1997-1114 Research & Women's Health
2004-0101 IFFGD Conference
2003-0401 IFFGD Research Awards
2003-0401 IBS Awareness
2001-0322 Patients First
1998-0401 IBS Millions Suffer
2002-0423 IBS-C Treatment
2002-1102 Heartburn Caution
2002-0402 IBS & Lost Potential
2002-0423 IBS in Real World
2001-1119 Heartburn or Heart Attack
Misunderstood Functional GI Disorders
IBS is No Joking Matter
For Media
Reporters' Guides
Media Contact Form

Our Mission

Education and Research

Our mission is to inform, assist and support people affected by gastrointestinal (GI) disorders.

IFFGD works with patients, families, physicians, health care professionals, and others to broaden understanding about gastrointestinal disorders and support or encourage research.

Awareness Activities & Accomplishments

Advocacy Activities

IFFGD Research Awards